Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-BCMA CAR-T cell
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Anti-BCMA CAR-T cell therapy is a form of adoptive cell immunotherapy where a patient's T cells are genetically modified to express a chimeric antigen receptor (CAR) specific for the B-cell maturation antigen (BCMA). BCMA is a protein predominantly expressed on the surface of mature B lymphocytes and plasma cells, and it is highly overexpressed in multiple myeloma. Upon infusion, these engineered T cells recognize BCMA-expressing cells, leading to T-cell activation, proliferation, and the targeted destruction of malignant plasma cells. This therapeutic approach has demonstrated significant efficacy in patients with relapsed or refractory multiple myeloma, leading to the regulatory approval of several specific CAR-T products such as idecabtagene vicleucel and ciltacabtagene autoleucel.
- Other names
- BCMA CAR-Tanti-BCMA CAR-TB-cell maturation antigen chimeric antigen receptor T-cell therapyBCMA-targeted CAR-T
02
Targets
BCMA (B-cell maturation antigen)GPRC5D
Beyond the preview
Go deeper on anti-BCMA CAR-T cell.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-BCMA CAR-T cell.